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Trends in anemia at initiation of dialysis in the United States. The introduction of human recombinant erythropoietin
Background. Anemia almost invariably develops in patients (rHuEPO) in July 1989 provided the first effective treat-
with chronic renal insufficiency (CRI) and is associated with a ment for the anemia of CRI [2]. Since then, treatmentwide range of complications. The anemia of CRI can be effectively
of anemia has been associated with partial regression oftreated with recombinant human erythropoietin (rHuEPO).
LVH, among both dialysis patients and patients withRecent studies suggest that the management of anemia of CRI
is suboptimal in the United States. CRI [3–5], and has been shown to reduce the frequency
Methods. We examined the trends in hematocrit and rHuEPO of cardiac complications, such as congestive heart failure
use among all patients who started chronic dialysis therapy (CHF) and the number of days of hospitalization amongbetween April 1, 1995, and December 31, 1999, from the End-
dialysis patients [6].stage Renal Disease Medical Evidence Form 2728 submitted
Despite the availability of rHuEPO for more than ato the Health Care Financing Administration of the United
States. Follow-up data containing hematocrit levels after initia- decade, recent studies have shown a high prevalence of
tion were obtained from the Medicare Part A institutional outpa- anemia in patients with end-stage renal disease (ESRD)
tient dialysis provider claims for 1990 to 1998 prevalent patients.
at initiation of dialysis. In a large cohort of patients whoResults. From June 1995 to June 1999, the mean hematocrit
began chronic dialysis in the United States between Aprilat initiation of dialysis increased from 28.1 to 29.3%. Likewise,
the annual percentage of patients receiving pre-dialysis rHuEPO 1995 and June 1997, 51% of patients had hematocrit
increased from 21.8 to 28.1%. Patients receiving predialysis levels less than 28% and 67% had hematocrit levels less
rHuEPO had a higher mean hematocrit than patients without than 30%. Overall, only 23% of patients had received
predialysis rHuEPO. The annual percentage of patients with
rHuEPO before the initiation of dialysis, and amonghematocrit24% fell 6.6% and the percentage with hematocrit
patients with hematocrit levels less than 28%, only 20%30% increased 9.2%. The trend toward higher hematocrit
levels has been consistent across all age, gender, and race catego- had received rHuEPO [7]. Despite a trend toward a
ries. Older patients, males, whites, and those who selected perito- higher hematocrit, management of anemia prior to initia-
neal dialysis had higher hematocrit levels than their counter- tion of dialysis appeared to be suboptimal during theparts. There were significant geographic differences in the
study period.prevalence of predialysis rHuEPO use.
In this article, we report the trends in anemia andConclusion. There has been a slight improvement in the man-
agement of anemia of CRI in the United States. However, a rHuEPO use at initiation of dialysis in the United States
considerable fraction of patients still have hematocrit levels that between January 1995 and December 1999.
are significantly lower than the currently recommended target.
Furthermore, improvement in the management of anemia could
result in improved clinical outcomes among patients with CRI. METHODS
Hematocrit at initiation of dialysis
Anemia almost invariably develops in patients with pro- Data source. Incident dialysis patients with a first end-
gressive chronic renal insufficiency (CRI), and it is associ- stage renal disease (ESRD) service date between April 1,
ated with a wide range of complications, particularly the 1995, and December 31, 1999, were studied. Data were
development of left ventricular hypertrophy (LVH) [1]. obtained from the Health Care Financing Administra-
tion (HCFA) Medical Evidence (2728) Form. A new ver-
sion of the Medical Evidence Form was implemented onKey words: hematocrit, hemodialysis, chronic renal insufficiency, end-
stage renal disease, erythropoietin, left ventricular hypertrophy. April 1, 1995, and only data from the new version were
selected for this study. For each patient, the first newReceived for publication April 19, 2001
Medical Evidence Form was selected, and only those withand in revised form June 12, 2001
Accepted for publication June 15, 2001 a physician’s signature within 12 months of the first ser-
vice date were included. Also, only patients with a Medi- 2001 by the International Society of Nephrology
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cal Evidence Form hematocrit measurement at dialysis 12 months of the first service date. Hematocrit data for
the first six months following the first ESRD service dateinitiation were included. Patient information was also
obtained from the Medical Evidence Form, including (months 1 to 6) were obtained from institutional outpa-
tient dialysis provider Medicare claims from January 1,dialysis type, age at first service date, gender, race, and
whether or not the patient received predialysis erythro- 1990, to June 30, 1999. Included patients had a first hema-
tocrit claim within 30 days following the first ESRD servicepoietin (rHuEPO). Patients were classified by their inci-
dent date according to the year and month of their first date and also had at least one claim with a hematocrit
measurement each month for six consecutive monthsESRD service date.
Trend analysis. For each month, patients incident dur- following the first service date. Therefore, all patients in
the trend analysis survived the full six-month period aftering the month were selected, and the mean hematocrit at
initiation of dialysis was calculated across patients. Mean initiation of dialysis.
Trend analysis. For each patient, the mean hematocrithematocrit was computed by the following: dialysis type
(all dialysis, hemodialysis and peritoneal dialysis, includ- for each month (months 1 to 6) was determined from
all hematocrit claims within the month. Then, for eaching intermittent, continuous ambulatory, and continuous
cycling), age (0 to 44, 45 to 64, 65 to 74, and 75 years), incident year, the mean hematocrit measurements at
month 0 (1995 to 1998 only) and months 1 to 6 weregender (female and male), race (black, white, and other),
and predialysis rHuEPO (no pre-dialysis rHuEPO and calculated across patients.
with predialysis rHuEPO). The respective analyses ex-
cluded patients with missing values for age or predialysis
RESULTS
rHuEPO. To assess further hematocrit trends across time,
Hematocrit at initiation of dialysisthe distribution of patients by hematocrit at initiation of
dialysis was analyzed. For each month, patients incident Trend analysis. Table 1 displays April 1995 to Decem-
ber 1999 incident dialysis patient characteristics basedduring the month were selected. The percentages of pa-
tients with a hematocrit measurement at dialysis initia- on Medical Evidence Form data. The total numbers of
incident dialysis patients having a 2728 Form hematocrittion within the following ranges were determined and
graphed as a sand diagram, a layered distribution graph measurement were 46,978 in 1995, 68,951 in 1996, 74,978
in 1997, 79,099 in 1998, and 64,077 in 1999 (1999 was in-of hematocrit groups across time: 24%, 24 to 27%,
27 to 30%, 30 to 33%, 33 to 36%, and 36%. complete secondary to delays in data entry from HCFA).
In 1999, the patients were distributed as follows: 15.1%U.S. maps. Maps showing geographic trends in pre-
dialysis rHuEPO were constructed from data developed were 0 to 44 years old; 35.1% were 45 to 64; 25.9% were
65 to 74; 23.8% were75; 53.3% were male; 63.4% wereon the level of health service areas (HSA). Data indicat-
ing whether or not the patient received pre-dialysis white; 28.6% were black; 44.8% had a primary cause of
ESRD of diabetes; 71.9% did not receive predialysisrHuEPO were combined for 1995 and 1996 incident dial-
ysis patients. For each HSA, the percentage of patients rHuEPO; and 90.9% were hemodialysis patients. Also,
in 1999, there were 15.2% of patients with a hematocritreceiving pre-dialysis rHuEPO was calculated. The
HSA-level data were then smoothed by application of measurement at dialysis initiation of 24%, 18.5% with
hematocrit 24 to 27%, 23.6% with hematocrit 27 tothe weighted head-banging method [8], weighting each
HSA-level percentage by the total number of included 30%, 20.1% with hematocrit 30 to 33%, and 22.7%
with hematocrit 33%.patients in the HSA. In order to display geographic pat-
terns, smoothed HSA-level data were divided into ap- Table 2 displays the prevalence of predialysis rHuEPO
use across different categories. Within each category,proximate quintiles and were mapped with graded col-
ors. A map was created with the percentage of 1995 the lowest percentage of patients receiving predialysis
rHuEPO was age 0 to 44, male, black, with a primaryand 1996 incident dialysis patients receiving pre-dialysis
rHuEPO, and methods were repeated for 1997 and 1998 cause of ESRD of hypertension, modality of hemodialy-
sis, and hematocrit 24%; in 1999, the respective per-patients.
centages of patients receiving pre-dialysis rHuEPO in
Hematocrit in the first six months following first these groups were 26.3, 26.7, 24.0, 24.3, 26.8, and 21.1%.
ESRD service date Comparing dialysis modalities, Figure 1 reveals the
trend in mean hematocrit at dialysis initiation for hemo-Data source. Incident ESRD patients from January 1,
1990, to December 31, 1998, were selected. Patients were dialysis, peritoneal dialysis, and all dialysis patients. He-
matocrit at dialysis initiation was consistently higher forclassified according to incident year, defined as the year
of the first ESRD service date. For the incident patients peritoneal dialysis than hemodialysis patients. In hemo-
dialysis, all dialysis and peritoneal dialysis patients, re-from 1995 to 1998, the hematocrit measurement at initia-
tion of therapy (month 0) was obtained from the most spectively, mean hematocrit was the following: 27.9, 28.1,
and 28.9% in June 1995; 28.4, 28.6, and 30.1% in Junerecent version of the Medical Evidence form filed within
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Table 1. April 1995 to December 1999 incident dialysis patients: Patient characteristics at dialysis initiation according to
HCFA Medical Evidence (2728) Form, by incident year
1995 1996 1997 1998 1999
N % N % N % N % N %
All (N  334,083) 46,978 68,951 74,978 79,099 64,077
Age
0–44 8,525 18.1 12,124 17.6 12,047 16.1 12,438 15.7 9,646 15.1
45–64 16,570 35.3 23,956 34.7 25,845 34.5 27,726 35.1 22,477 35.1
65–74 12,699 27.0 18,814 27.3 20,530 27.4 20,915 26.4 16,577 25.9
75 9,114 19.4 13,943 20.2 16,422 21.9 17,864 22.6 15,269 23.8
Missing 70 0.1 114 0.2 134 0.2 156 0.2 108 0.2
Gender
Female 22,433 47.8 32,236 46.8 35,114 46.8 37,032 46.8 29,948 46.7
Male 24,545 52.2 36,715 53.2 39,864 53.2 42,067 53.2 34,129 53.3
Race
Black 14,046 29.9 20,777 30.1 21,882 29.2 23,233 29.4 18,347 28.6
White 28,296 60.2 41,494 60.2 46,540 62.1 49,003 62.0 40,639 63.4
Other 4,636 9.9 6,680 9.7 6,556 8.7 6,863 8.7 5,091 7.9
Primary cause of ESRD
Diabetes 19,983 42.5 30,046 43.6 33,133 44.2 35,175 44.5 28,699 44.8
Hypertension 12,282 26.1 18,120 26.3 20,019 26.7 21,042 26.6 17,087 26.7
Glomerulonephritis 5,227 11.1 7,428 10.8 7,545 10.1 7,669 9.7 6,002 9.4
Other 9,486 20.2 13,357 19.4 14,281 19.0 15,213 19.2 12,289 19.2
Predialysis rHuEPO
No 36,708 78.1 52,690 76.4 56,690 75.6 58,310 73.7 46,041 71.9
Yes 10,263 21.8 16,257 23.6 18,283 24.4 20,788 26.3 18,035 28.1
Missing 7 0.0 4 0.0 5 0.0 1 0.0 1 0.0
Dialysis modality
HD 39,926 85.0 59,922 86.9 66,566 88.8 71,368 90.2 58,246 90.9
PD 7,052 15.0 9,029 13.1 8,412 11.2 7,731 9.8 5,831 9.1
Hematocrit %
24 10,251 21.8 14,299 20.7 13,396 17.9 13,207 16.7 9,708 15.2
24–27 10,055 21.4 14,792 21.5 15,420 20.6 15,463 19.5 11,844 18.5
27–30 10,887 23.2 16,094 23.3 18,038 24.1 19,019 24.0 15,143 23.6
30–33 8,041 17.1 11,958 17.3 13,992 18.7 15,436 19.5 12,857 20.1
33 7,744 16.5 11,808 17.1 14,132 18.8 15,974 20.2 14,525 22.7
1997; and 29.2, 29.3, and 31.0% in June 1999. The gap respectively, mean hematocrit was the following: 26.8,
28.8, and 27.2% in June 1995; 27.8, 29.1, and 28.1% inin hematocrit between the two modalities appears to be
widening across time: Hematocrit was 0.8% higher in June 1997; 28.1, 29.9, and 29.2% in June 1999.
Patients receiving predialysis rHuEPO displayed gen-peritoneal dialysis than hemodialysis patients in April
1995, and 2.0% higher in peritoneal dialysis than hemodi- erally higher mean hematocrits than patients without
predialysis rHuEPO (Fig. 5). For those with and withoutalysis patients in December 1999.
Figures 2 through 4 show trends in hematocrit by age, predialysis rHuEPO, respectively, mean hematocrit was
the following: 29.1 and 27.8% in June 1995; 29.5 andgender, and race. Figure 2 displays the trend in mean
hematocrits for patients by age at initiation of dialysis, 28.3% in June 1997; and 30.3 and 28.9% in June 1999.
Figures 1 through 5 illustrate a general trend of stableand the older age groups generally showed higher mean
hematocrits, than the younger age groups. Mean hemato- hematocrit at initiation of dialysis in 1995 followed by
increasing hematocrit from 1996 to 1999. Figure 6 alsocrit was the following in patients 0 to 44, 45 to 64, 65 to
74, and 75 years of age, respectively: 26.5, 28.0, 28.5, shows this trend with a decreasing percentage of patients
with hematocrit24% and an increasing percentage withand 28.9% in June 1995; 27.3, 28.3, 29.2, and 29.3% in
June 1997; and 27.9, 29.1, 29.9, and 30.0% in June 1999. hematocrit 30% from 1996 to 1999. For June of each
year, the percentages of patients with hematocrit 24%Figure 3 reveals a higher mean hematocrit in males than
in females. For males and females, respectively, mean were 21.3% in 1995, 21.1% in 1996, 17.4% in 1997, 16.4%
in 1998, and 15.0% in 1999, and the percentages of pa-hematocrit was the following: 28.3 and 27.8% in June
1995; 28.8 and 28.4% in June 1997; and 29.6 and 29.1% tients with hematocrit30% were 35.2% in 1995, 34.0%
in 1996, 38.6% in 1997, 41.3% in 1998, and 44.4% in 1999.in June 1999. Differences in mean hematocrit among race
groups are displayed in Figure 4, and whites had consis- U.S. Maps. Figure 7 shows the geographic distribution
of the percentage of patients receiving pre-dialysistently higher mean hematocrits than blacks (1.8% higher
in January 1999). For blacks, whites, and other races, rHuEPO. As shown in Table 1, the percentage of incident
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Table 2. April 1995 to December 1999 incident dialysis patients: lack in improvement in the hematocrit levels in 1997 is
Percentage patients receiving pre-dialysis rHuEPO according to
coincident to the period when HCFA had implementedHCFA Medical Evidence (2728) Form, by patient
characteristics and incident year the Hematocrit Measurement Audit program.
1995 1996 1997 1998 1999
Age DISCUSSION
0–44 20.1 21.8 22.3 23.5 26.3
Our results demonstrate that there has been a steady45–64 21.5 23.4 24.7 26.5 28.3
65–74 22.9 24.3 25.1 27.8 29.3 increase in mean hematocrit levels and rHuEPO use
75 22.6 24.4 24.4 26.2 27.8 among incident dialysis patients in the United States.
Missing 24.3 30.7 24.6 31.4 35.2
From June 1995 to June 1999, the mean hematocrit atGender
Female 23.7 25.4 26.4 28.1 29.8 initiation of dialysis increased from 28.1 to 29.3%. Like-
Male 20.1 22.0 22.6 24.7 26.7 wise, the annual percentage of patients receiving predial-
Race
ysis rHuEPO increased from 21.8 to 28.1%. PatientsBlack 17.7 19.4 20.5 21.9 24.0
White 23.8 25.6 26.2 28.3 30.3 receiving predialysis rHuEPO had a higher mean hema-
Other 22.4 24.0 24.8 26.8 26.2 tocrit than patients without pre-dialysis rHuEPO. These
Primary cause of ESRD
changes have resulted in a stable trend towards a de-Diabetes 23.6 25.7 26.3 28.5 30.3
Hypertension 18.6 20.3 21.4 22.7 24.3 creasing percentage of incident dialysis patients with
Glomerulonephritis 24.4 26.1 26.8 29.0 31.1 hematocrit24% and an increasing percentage with he-
Other 21.0 21.8 22.8 24.6 27.0
matocrit 30%. Indeed, between 1995 and 1999, theDialysis modality
HD 20.2 22.0 23.1 25.0 26.8 annual percentage of patients with hematocrit 24% at
PD 31.0 34.4 34.8 38.5 41.5 initiation of dialysis fell 6.6% and the percentage with
Hematocrit %
hematocrit 30% increased 9.2%. The trend toward24 16.8 18.3 18.8 19.1 21.1
24–27 19.8 21.3 21.9 23.0 24.4 higher hematocrit levels has been consistent across all age,
27–30 22.5 23.3 24.2 25.7 27.3 gender, and race categories.
30–33 25.1 26.8 27.4 29.5 30.1
Despite the trend toward increasing mean hematocrit33 26.8 29.9 29.6 32.9 35.0
levels and rHuEPO use, a high proportion of ESRDTotal patient counts for each cell are shown as N in Table 1.
patients in the United States are started on renal replace-
ment therapy at hematocrit levels that are significantly
lower than currently recommended levels. The National
patients receiving pre-dialysis rHuEPO increased from Kidney Foundation-Dialysis Outcomes Quality Initia-
21.8% in 1995, to 23.6% in 1996, to 24.4% in 1997, to tive (NKF-DOQI) Guidelines recommend a target he-
26.3% in 1998. This trend also is visible in areas of the matocrit level of 33 to 36% for both pre-dialysis and
western and northeastern United States, where there dialysis patients [9]. The European Best Practice Guide-
has been an increase in HSAs with 26% of patients lines recommend a threshold hematocrit level for initia-
receiving predialysis rHuEPO from 1995 and 1996 (data tion of rHuEPO therapy of 33% for both patients on
not shown) to 1997 and 1998 (Fig. 7). Areas of the central dialysis and those with CRI [10]. The Canadian Medical
and southern U.S. had the fewest patients (18%) re- Association Guidelines recommend a target hemoglobin
ceiving pre-dialysis rHuEPO in 1997 and 1998. level of 11 to 12 g/dL (hematocrit, 33 to 36%) during
rHuEPO therapy for predialysis patients, particularly if
Hematocrit in the first six months following first they are symptomatic or have cardiovascular complica-
ESRD service date tions [11]. Our study revealed that in 1999, the percent-
Figure 8 presents hematocrit data for 1990 to 1998 age of patients who were started on dialysis with hemato-
incident ESRD patients who received rHuEPO consis- crit levels 30%, 30 to 33%, and 33% was 57.3, 20.1,
tently for the first six months following the first ESRD and 22.7%, respectively. Consequently, more than three
service date, and the legend of Figure 8 indicates the fourths of patients began renal replacement therapy at
sample size for each incident year. Mean hematocrit hematocrit levels below the currently recommended levels.
levels increased from month 0 to approximately month 4, Although the ideal target hematocrit and the appro-
and stabilized during months 4 to 6. Hematocrit generally priate timing for initiation of rHuEPO therapy for the
increased with increasing incident year. For month 0, anemia of CRI are still debated, there does not appear
mean hematocrit from the Medical Evidence Form was to be a sound rationale for waiting until the development
27.6% in 1995, 27.9% in 1996, 28.3% in 1997, and 28.7% of potentially irreversible complications and profound
in 1998. For months 1 to 6, respectively, mean hematocrit symptoms of anemia before beginning rHuEPO therapy.
was the following: 27.3, 28.6, 29.3, 29.6, 29.5, and 29.4% However, most third-party payers in the U.S. do not begin
in 1990; 28.7, 29.9, 30.8, 31.2, 31.3, and 31.3% in 1994; to cover the cost of rHuEPO therapy until the hematocrit
level has fallen below 30%. In countries in which thisand 29.8, 31.6, 33.2, 33.8, 34.0, and 33.9% in 1998. The
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Fig. 1. April 1995 to December 1999 incident
dialysis patients. Mean hematocrit at dialysis
initiation, based on the HCFA Medical Evi-
dence Form, by dialysis type and month of first
service date. Symbols are: (solid line) hemodi-
alysis; (dashed line) peritoneal dialysis; ()
all dialysis.
Fig. 2. April 1995 to December 1999 incident
dialysis patients. Mean hematocrit at dialysis
initiation, based on the HCFA Medical Evi-
dence Form, by patient age at initiation and
month of first service date. Symbols are: ()
0 to 44; () 45 to 64; (solid line) 65 to 74;
(dashed line) 75.
particular fiscal concern may not be operative, it would rHuEPO was much higher than that of HD patients (41.5
vs. 26.8% in 1999). This is consistent with our previousbe reasonable to begin therapy once the hematocrit levels
decrease to 33 to 36% (hemoglobin, 11 to 12 g/dL) and analysis using HCFA 2728 form data, which showed that
PD patients were less likely to have a hematocrit lessaim to maintain patients at those levels. More firm rec-
ommendations regarding optimal hematocrit/hemoglo- than 28% at initiation of dialysis, and more likely to have
received pre-dialysis rHuEpo than HD patients. Webin levels can only be made once data supporting the
benefits of maintaining higher hematocrit levels in CRI speculated that these differences could be explained by
a selection bias, as PD patients are more likely to bepatients emerges. This could prompt revision of current
payer policies [12]. white and have private insurance compared with HD
patients. However, after adjusting for these and otherOur analysis revealed a trend towards a higher mean
hematocrit among patients who selected PD compared factors in a multivariate regression analysis, the differ-
ences between the two groups persisted, suggesting thatto those who selected HD as initial ESRD therapy. In-
deed, the mean hematocrit was 0.8% higher in PD than other factors may be operative [7]. A factor that could
explain the differences in mean hematocrit and rHuEPOin HD patients in April 1995 and 2.0% higher in PD
than in HD patients in December 1999. We also found use between PD and HD patients is that patients who
select PD are more likely to have received pre-ESRDthat the percentage of PD patients receiving pre-dialysis
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Fig. 3. April 1995 to December 1999 incident
dialysis patients. Mean hematocrit at dialysis
initiation, based on the HCFA Medical Evi-
dence Form, by gender and month of first
service date. Symbols are: (solid line) female;
(dashed line) male.
Fig. 4. April 1995 to December 1999 incident
dialysis patients. Mean hematocrit at dialysis
initiation, based on the HCFA Medical Evi-
dence Form, by race and month of first service
date. Symbols are: () black; (dashed line)
white; (solid line) other.
care by a nephrologist [13]. In a recent study of 135 males, and whites had significantly higher mean hemato-
crit levels at the initiation of dialysis than their counter-patients who began dialysis at the New England Medical
Center between 1992 and 1997, patients who were re- parts. Additionally, there were higher percentages of older
patients (greater than 44 years of age), females, and whitesferred early (4 months prior to initiation of dialysis)
to the nephrologist were less likely to have hematocrit that received predialysis rHuEPO as compared with
younger patients, males, and blacks. In a previous analysisless than 28% at the initiation of dialysis and more likely
to have received predialysis rHuEPO compared with using HCFA 2728 form data, we found that the adjusted
odds of having a hematocrit 28% (severe anemia) atpatients who were referred late (4 months prior to
the initiation of dialysis) [14]. Thus, the specialty of the the initiation of dialysis were lower among patients 40
to 64 and 65 compared with patients 18 to 39 years ofphysician and the timing of referral to a nephrologist
influence the quality of pre-ESRD care, including the age (OR 0.78 and 0.64, respectively; P 0.05). However,
there were no significant differences in the odds of re-correction of anemia.
Another finding of this study was that older patients, ceiving pre-dialysis rHuEPO among these age groups
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Fig. 5. April 1995 to December 1999 incident
dialysis patients. Mean hematocrit at dialysis
initiation, based on the HCFA Medical Evi-
dence Form, by pre-dialysis rHuEPO and
month of first service date. Symbols are (solid
line) no predialysis EPO; (dashed line) with
predialysis EPO.
Fig. 6. April 1995 to December 1999 incident
dialysis patients. Percent patients by hemato-
crit at dialysis initiation, based on the HCFA
Medical Evidence Form, by month of first ser-
vice date.
[7]. The lower prevalence of severe anemia in the older be explained by medical insurance or employment, as
the differences remained significant after controlling forage groups may be explained by earlier intervention (not
necessarily rHuEPO therapy) due to a higher prevalence these and other factors in a multivariate regression model.
Possible reasons for the influence of gender and race onof comorbid conditions, particularly cardiovascular dis-
ease. In the previous analysis we found that women also anemia management include reduced access to care and
other economic factors unrelated to insurance, patients’were more likely to have severe anemia at the initiation
of dialysis and more likely to have received pre-dialysis attitudes toward seeking or accepting medical care, and
physician referral patterns. Another factor that may ac-rHuEPO compared to males (OR 1.15 and 1.28, respec-
tively; P  0.05). Likewise, blacks were more likely to count for the racial differences is that the mean hemoglo-
bin level of healthy blacks of both sexes and all ageshave severe anemia and less likely to have received pre-
dialysis rHuEPO compared to whites (OR 1.40 and 0.84; tends to be 0.5 to 1.0 g/dl below the mean for comparable
whites [15, 16]. Other investigators have reported genderP 0.05). These gender and racial differences could not
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Fig. 7. The 1997 and 1998 incident dialysis patients. Percent patients receiving pre-dialysis rHuEPO, based on the HCFA Medical Evidence Form,
by health service area (HSA).
Fig. 8. The 1990 to 1998 incident ESRD pa-
tients who received rHuEPO in the first 6
months of ESRD. Mean hematocrit by year
of incidence and month following first ESRD
service date. *Month 0 shows mean hemato-
crit from HCFA Medical Evidence Form.
and racial differences in various aspects of access to and Regional differences also have been observed with re-
spect to other indices of pre-ESRD care, such as place-intensity of medical care as well [17–22].
Significant geographic differences in the prevalence of ment of permanent vascular access for dialysis, hypoal-
buminemia, and late initiation of dialysis [7, 22, 23]. TherHuEPO use were observed in this study, suggesting
regional variations in practice patterns or reimbursement. reasons for the regional differences in the prevalence of
rHuEPO use are unclear and require further investiga-A trend toward higher percentages of patients receiving
pre-dialysis rHuEPO was evident in areas of the western tion.
Finally, we observed that the mean hematocrit in-and northeastern U.S. In contrast, areas of the central
and southern United States had the fewest patients re- creased during the first four months and then stabilized
during months four to six after the onset of dialysis. Inter-ceiving predialysis rHuEPO in 1997 and 1998 (18%).
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estingly, patients who had higher hematocrit levels at incident ESRD patients in the highest hematocrit quintile
(adjusted OR 0.67, 95% CI, 0.51 to 0.89). The most sig-month 0 achieved higher hematocrit levels at month 6.
The mean hematocrit levels at months 1 through 6 were nificant effect of pre-ESRD rHuEPO use was observed
during the first 19 months after starting dialysis (adjustedalmost identical in 1996 and 1997. The lack of improve-
ment in hematocrit levels in 1997 is coincident to the OR 0.81, 95% CI, 0.71 to 0.91), but this benefit dimin-
ished in patients with longer follow-up on renal replace-period when HCFA had implemented the Hematocrit
Measurement Audit (HMA), which restricted Medicare ment therapy. It is likely that the beneficial effects of
rHuEPO use on survival reported in this study may bepayment of rHuEPO when the “rolling” or average
3-month hematocrit exceeded 36.5%. The NKF-DOQI related to better pre-ESRD care.
Our results should be interpreted in light of the follow-guidelines, which recommended a target hematocrit range
of 33 to 36%, were published in the fall of 1997. In ing limitations. First, the hematocrit data at initiation of
dialysis has not been validated. Second, the HCFA 2728addition, the HMA was rescinded in 1998. Both of these
factors probably contributed to the increase in hemato- Form question “Was pre-dialysis/transplant EPO admin-
istered?” is ambiguous and does not provide informationcrit levels seen in 1998 and 1999. The improvement in
hematocrit levels after ESRD is not unexpected as most on the frequency of rHuEPO use prior to initiation of
dialysis. However, in a previous analysis using HCFApatients receive rHuEPO therapy once they enter a
chronic dialysis program. It is disturbing, however, that 2728 Form data, we found a clear inverse correlation
between the prevalence of rHuEPO use and that of he-more than three-fourths of the patients who start chronic
dialysis in the United States have hematocrit levels well matocrit 28% at the initiation of dialysis among most
ESRD networks (r  0.65, P  0.004), which arguesbelow the recommended target for patients on dialysis.
Several studies have shown that anemia develops early against significant misclassification [7].
In summary, the results of this study reveal that man-in the course of CRI and that it is an independent risk
factor for the development of left ventricular hypertro- agement of anemia of CRI improved in the United States
between 1995 and 1999. The trend towards a higherphy (LVH) [24, 25]. LVH is present in up to 74% of
patients at initiation of renal replacement therapy and hematocrit at initiation of dialysis has been consistent
across different age, gender, race, and initial dialysisis an important predictor of cardiovascular morbidity and
mortality among patients undergoing dialysis [26, 27]. modality categories. However, a sizable fraction of pa-
tients still have hematocrit levels at initiation of renalTreatment of anemia with rHuEPO has been shown to
result in partial regression of LVH, both in dialysis and replacement therapy that are significantly lower than the
currently recommended levels. Further improvement inCRI patients, and has reduced the frequency of cardiac
complications such as congestive heart failure, the num- the management of anemia could result in improved
clinical outcomes among patients with CRI.ber of hospital days required for dialysis patients, and
mortality levels [3–6, 12, 28, 29]. Consequently, the low
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